Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(2):287–294. doi: 10.1038/bjc.1997.47

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

N Siddiqui 1, A V Boddy 1, H D Thomas 1, N P Bailey 1, L Robson 1, M J Lind 1, A H Calvert 1
PMCID: PMC2063279  PMID: 9010040

Abstract

The aim of this phase I study was to determine the maximum tolerated dose of a 3-h infusion of paclitaxel, combined with carboplatin at a fixed AUC of 7 mg ml-1 min every 4 weeks for up to six cycles and to evaluate any possible pharmacokinetic interaction. Twelve chemonaive patients with ovarian cancer were treated with paclitaxel followed by a 30-min infusion of carboplatin. Paclitaxel dose was escalated from 150 mg m-2 to 225 mg m-2 in cohorts of three patients. Carboplatin dose was based on renal function. Pharmacokinetic studies were performed in nine patients (at least two at each dose level). A total of 66 courses were evaluable for assessment. Grade 3 or 4 neutropenia was seen in 70% of the courses, however hospitalization was not required. Grade 3 or 4 thrombocytopenia occurred in 24% of the courses. Alopecia, myalgia and peripheral neuropathy were common but rarely severe. The pharmacokinetics of paclitaxel was non-linear and did not appear to be influenced by co-administration of carboplatin. The AUC of carboplatin was 7.0 +/- 1.4 mg ml-1 min, indicating that there was no pharmacokinetic interaction. The combination of carboplatin and paclitaxel may be administered as first-line treatment for advanced ovarian cancer. Although myelosuppression is the dose-limiting toxicity of the component drugs, the severity of thrombocytopenia was less than anticipated. The results of this study, with only a small number of patients, need to be confirmed in future investigations.

Full text

PDF
287

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M., Kerby I. J., Rocker I., Evans A., Johansen K., Franks C. R. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol. 1989;28(1):57–60. doi: 10.3109/02841868909111182. [DOI] [PubMed] [Google Scholar]
  2. Caldas C., McGuire W. P., 3rd Paclitaxel (Taxol) therapy in ovarian carcinoma. Semin Oncol. 1993 Aug;20(4 Suppl 3):50–55. [PubMed] [Google Scholar]
  3. Calvert A. H., Newell D. R., Gumbrell L. A., O'Reilly S., Burnell M., Boxall F. E., Siddik Z. H., Judson I. R., Gore M. E., Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748–1756. doi: 10.1200/JCO.1989.7.11.1748. [DOI] [PubMed] [Google Scholar]
  4. Cavaletti G., Bogliun G., Marzorati L., Zincone A., Marzola M., Colombo N., Tredici G. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995 Mar 1;75(5):1141–1150. doi: 10.1002/1097-0142(19950301)75:5<1141::aid-cncr2820750514>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  5. Crook M., Crawford N. Electrokinetic, analytical and functional heterogeneity of circulating human platelets: separation of subpopulations by continuous flow electrophoresis after taxol stabilization. Biochim Biophys Acta. 1989 Oct 30;1014(1):26–39. doi: 10.1016/0167-4889(89)90237-1. [DOI] [PubMed] [Google Scholar]
  6. Ghazal-Aswad S., Calvert A. H., Newell D. R. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol. 1996;37(5):429–434. doi: 10.1007/s002800050408. [DOI] [PubMed] [Google Scholar]
  7. Gianni L., Kearns C. M., Giani A., Capri G., Viganó L., Lacatelli A., Bonadonna G., Egorin M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol. 1995 Jan;13(1):180–190. doi: 10.1200/JCO.1995.13.1.180. [DOI] [PubMed] [Google Scholar]
  8. Harland S. J., Newell D. R., Siddik Z. H., Chadwick R., Calvert A. H., Harrap K. R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed] [Google Scholar]
  9. Havrilesky L. J., Elbendary A., Hurteau J. A., Whitaker R. S., Rodriguez G. C., Berchuck A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol. 1995 Jun;85(6):1007–1010. doi: 10.1016/0029-7844(95)00058-y. [DOI] [PubMed] [Google Scholar]
  10. Huizing M. T., Keung A. C., Rosing H., van der Kuij V., ten Bokkel Huinink W. W., Mandjes I. M., Dubbelman A. C., Pinedo H. M., Beijnen J. H. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127–2135. doi: 10.1200/JCO.1993.11.11.2127. [DOI] [PubMed] [Google Scholar]
  11. McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
  12. O'Brien J. M., Jr, Wewers M. D., Moore S. A., Allen J. N. Taxol and colchicine increase LPS-induced pro-IL-1 beta production, but do not increase IL-1 beta secretion. A role for microtubules in the regulation of IL-1 beta production. J Immunol. 1995 Apr 15;154(8):4113–4122. [PubMed] [Google Scholar]
  13. Rowinsky E. K., Chaudhry V., Forastiere A. A., Sartorius S. E., Ettinger D. S., Grochow L. B., Lubejko B. G., Cornblath D. R., Donehower R. C. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993 Oct;11(10):2010–2020. doi: 10.1200/JCO.1993.11.10.2010. [DOI] [PubMed] [Google Scholar]
  14. Rowinsky E. K., Gilbert M. R., McGuire W. P., Noe D. A., Grochow L. B., Forastiere A. A., Ettinger D. S., Lubejko B. G., Clark B., Sartorius S. E. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991 Sep;9(9):1692–1703. doi: 10.1200/JCO.1991.9.9.1692. [DOI] [PubMed] [Google Scholar]
  15. Sarosy G., Kohn E., Stone D. A., Rothenberg M., Jacob J., Adamo D. O., Ognibene F. P., Cunnion R. E., Reed E. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992 Jul;10(7):1165–1170. doi: 10.1200/JCO.1992.10.7.1165. [DOI] [PubMed] [Google Scholar]
  16. Thigpen T., Vance R., Puneky L., Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97–107. doi: 10.1006/gyno.1994.1347. [DOI] [PubMed] [Google Scholar]
  17. Trimble E. L., Adams J. D., Vena D., Hawkins M. J., Friedman M. A., Fisherman J. S., Christian M. C., Canetta R., Onetto N., Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 1993 Dec;11(12):2405–2410. doi: 10.1200/JCO.1993.11.12.2405. [DOI] [PubMed] [Google Scholar]
  18. Tuxen M. K., Sölétormos G., Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995 May;21(3):215–245. doi: 10.1016/0305-7372(95)90002-0. [DOI] [PubMed] [Google Scholar]
  19. Wild M. D., Walle U. K., Walle T. Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol. 1995;36(1):41–44. doi: 10.1007/BF00685730. [DOI] [PubMed] [Google Scholar]
  20. Wiltshaw E., Evans B., Rustin G., Gilbey E., Baker J., Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol. 1986 May;4(5):722–729. doi: 10.1200/JCO.1986.4.5.722. [DOI] [PubMed] [Google Scholar]
  21. Wiltshaw E., Subramarian S., Alexopoulos C., Barker G. H. Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1545–1548. [PubMed] [Google Scholar]
  22. Woods C. M., Zhu J., McQueney P. A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995 Jul;1(5):506–526. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES